BarrettHChildsMD

PubMed

• 6 citations
  Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian ca...
  Alessandro D Santin, Ignace Vergote, Antonio González-Martín, Kathleen Moore, Ana Oaknin, Ignacio Romero, Sami Diab, Larry J Copeland, Bradley J Monk, Robert L Coleman...> ;International Journal of Gynecological Cancer. 2023 Apr 3
• 1 citations
  PI3K inhibitors in haematological malignancies.
  Matthew J Matasar, Florian Hiemeyer, Barrett H Childs, Pier Luigi Zinzani> ;The Lancet. Oncology. 2022 Aug 1
• 4 citations
  A phase I pharmacokinetic study of copanlisib in Chinese patients with relapsed indolent non-Hodgkin lymphoma.
  Weiping Liu, Lingyan Ping, Yan Xie, Yingli Sun, Tingting Du, Yi Niu, Galia Cisternas, Funan Huang, Jose Garcia-Vargas, Barrett H Childs, Aruna Mehra, Susanne Reschke, ...> ;Cancer Chemotherapy and Pharmacology. 2022 Jun 1
• 19 citations
  Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
  Hedy L Kindler, Silvia Novello, Alessandra Bearz, Giovanni L Ceresoli, Joachim G J V Aerts, James Spicer, Paul Taylor, Kristiaan Nackaerts, Alastair Greystoke, Ross Je...> ;The Lancet. Oncology. 2022 Apr 1
• 8 citations
  Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma
  Matthew J. Matasar, Martin Dreyling, Sirpa Leppä, Armando Santoro, Michael Pedersen, Viktoriya Buvaylo, Monique Fletcher, Barrett H. Childs, Pier Luigi Zinzani> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jul 2
• 70 citations
  Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-contro...
  Matthew J. Matasar, Marcelo Capra, Muhit Ozcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, T. Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, ...> ;The Lancet. Oncology. 2021 May 1
• 7 citations
  Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
  Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, Cornelis M. van Tilburg, Birgit Geoerger, Ulrik Lassen, Russell J. Schilder, Brian Turpin, Shivani Nanda, Karen Keatin...> ;Current Problems in Cancer. 2021 Apr 2
• 14 citations
  Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.
  Panayiotis Panayiotidis, George A Follows, Luigina Mollica, Arnon Nagler, Muhit Ozcan, Armando Santoro, Don A. Stevens, David Trevarthen, Florian Hiemeyer, J. Garcia-V...> ;Blood Advances. 2021 Feb 9
• 16 citations
  Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis.
  Antoine Italiano, Shivani Nanda, Andrew Briggs, Jesús García-Foncillas, Ulrik Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, David S. Hong, Theodore ...> ;Cancers. 2020 Nov 4
• 490 citations
  Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
  David S. Hong, Steven G. DuBois, Shivaani Kummar, Anna F. Farago, Catherine M. Albert, Kristoffer Staal Rohrberg, Cornelis M. van Tilburg, Ramamoorthy Nagasubramanian,...> ;The Lancet. Oncology. 2020 Apr 1
• 95 citations
  Long‐term safety and efficacy of the PI3K‐ inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2‐year follow‐up of the CHRONOS‐1 study
  Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Maria Dimou, Judit Demeter, Muhit Ozcan, Mari...> ;American Journal of Hematology. 2020 Apr 1
• 84 citations
  First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid...
  Raffit Hassan, George R. Blumenschein, Kathleen N. Moore, Alessandro D. Santin, Hedy L. Kindler, John Nemunaitis, Shelly Seward, Anish Thomas, Stella K. Kim, Prabhu Ra...> ;Journal of Clinical Oncology. 2020 Mar 26
• 39 citations
  Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymp...
  Georg Lenz, Eliza A Hawkes, Gregor Verhoef, Corinne Haioun, Soon Thye Lim, Dae Seog Heo, Kirit M. Ardeshna, Geoffrey Chong, Jacob Haaber, Wei Shi, Igor Gorbatchevsky, ...> ;Leukemia. 2020 Feb 14
• 45 citations
  Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-mutated Hepatocellular Carcinoma
  Ho Yeong Lim, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul Ross, Vincenzo Mazzaferro, Jean-Frédéric Blanc, Yuk Ting Ma, Chia Jui Yen, Judit Kocsis, Su Pin Choo, ...> ;Clinical Cancer Research. 2018 Oct 1
• 264 citations
  Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
  Martin Dreyling, Armando Santoro, Luigina Mollica, Sirpa Leppä, George A. Follows, Georg Lenz, Won Seog Kim, Arnon Nagler, Panayiotis Panayiotidis, Judit Demeter, Muhi...> ;Journal of Clinical Oncology. 2017 Oct 4
• 183 citations
  Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
  Martin Dreyling, Franck Morschhauser, Krimo Bouabdallah, Dominique Bron, David Cunningham, Sarit Assouline, Gregor Verhoef, Kim Linton, Catherine Thieblemont, Umberto ...> ;Annals of Oncology. 2017 Sep 1
• 43 citations
  Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
  Jean-Luc Van Laethem, Hanno Riess, Jacek Jassem, Michael Haas, Uwe M. Martens, Colin D. Weekes, Marc Peeters, Paul Ross, John Bridgewater, Bohuslav Melichar, Stefano C...> ;Targeted Oncology. 2017 Feb 1
• 43 citations
  Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT
  Howard S. Hochster, Axel Grothey, Lowell L. Hart, Kendrith M. Rowland, Rafat Ansari, Steven R. Alberts, N. M. Chowhan, Ramesh K. Ramanathan, M. Keaton, John D. Hainswo...> ;Annals of Oncology. 2014 Jun 1
• 10 citations
  Phase II multicenter study of docetaxel and bevacizumab with or without trastuzumab as first-line treatment for patients with metastatic breast cancer.
  Lee S. Schwartzberg, Suprith Badarinath, Mark Keaton, Barrett H. Childs> ;Clinical Breast Cancer. 2014 Jun 1
• 5 citations
  Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
  Denise A. Yardley, Lowell L. Hart, David M. Waterhouse, Robert C. Whorf, D. Randolph Drosick, Patrick Murphy, Suprith Badarinath, Brooke R. Daniel, Barrett H. Childs, ...> ;Breast Cancer Research and Treatment. 2013 Nov 21
• 161 citations
  Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial
  John R. Mackey, Miguel Martin, Tadeusz Pienkowski, Janusz Rolski, Jean-Paul Guastalla, Amer Sami, John A. Glaspy, Eva Juhos, Andrew M Wardley, Tommy Fornander, John D....> ;The Lancet. Oncology. 2013 Jan 1
• 14 citations
  Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer.
  Sumanta K. Pal, Barrett H. Childs, Mark D. Pegram> ;Breast Cancer Research and Treatment. 2010 Jan 1
• 455 citations
  Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TR...
  Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen Lee Cohn, Lucas Wong, Louis Fehrenbacher, Yousif A. Abubakr, M. ...> ;Journal of Clinical Oncology. 2008 Jul 20
• 103 citations
  Use of Calcium and Magnesium Salts to Reduce Oxaliplatin-Related Neurotoxicity
  Howard S. Hochster, Axel Grothey, Barrett H. Childs> ;Journal of Clinical Oncology. 2007 Sep 1
• 22 citations
  High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
  Lauren E. Abrey, Barrett H. Childs, Nina Paleologos, L. Kaminer, Steven S. Rosenfeld, Donna Salzman, Jonathan L. Finlay, Sharon Gardner, Kendra Peterson, Wendy W. Hu, ...> ;Neuro-Oncology. 2006 Apr 1
• Join now to see all

Lectures

• Long-Term Efficacy and Safety from the Copanlisib CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcomes for Patients with Pre-Existing Diabetes or Hypertension Treated with Copanlisib from the CHRONOS- Study in Patients with Relapsed or Refractory Indolent B-Cel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018